desmopressin acetate - Profile

What are the generic sources for desmopressin acetate and what is the scope of freedom to operate?

Desmopressin acetate is the generic ingredient in eleven branded drugs marketed by Nordic Pharma, Am Regent, Bedford, Dr Reddys, Gland, Hospira, Meitheal, Sagent Pharms Inc, Sun Pharm Inds Ltd, UBI, Ferring, Ferring Pharms Inc, Sun Pharm Inds, Bausch, Apotex, Sun Pharm, Zydus Pharms, Acerus Pharms, Abhai Llc, Actavis Labs Fl Inc, Aurobindo Pharma, Glenmark Pharms Ltd, Heritage Pharma, Impax Labs Inc, Natco Pharma Usa, and Novast Labs, and is included in thirty-six NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Desmopressin acetate has one hundred and sixty-seven patent family members in twenty-eight countries.

Summary for desmopressin acetate

International Patents:	167
US Patents:	7
Tradenames:	11
Applicants:	26
NDAs:	36
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for desmopressin acetate

US Patents and Regulatory Information for desmopressin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nordic Pharma	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938-001	Mar 30, 1984	AP	RX	Yes	Yes
Nordic Pharma	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938-002	Apr 25, 1995		DISCN	No	No
Am Regent	DESMOPRESSIN ACETATE	desmopressin acetate	INJECTABLE;INJECTION	091374-001	Feb 14, 2019		DISCN	No	No
Bedford	DESMOPRESSIN ACETATE	desmopressin acetate	INJECTABLE;INJECTION	074575-001	Feb 18, 2000		DISCN	No	No

Expired US Patents for desmopressin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-002	Sep 6, 1995
Ferring Pharms Inc	DDAVP	desmopressin acetate	SOLUTION;NASAL	017922-001	Approved Prior to Jan 1, 1982
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-001	Sep 6, 1995
Acerus Pharms	NOCTIVA	desmopressin acetate	SPRAY, METERED;NASAL	201656-002	Mar 3, 2017

International Patents for desmopressin acetate

Country	Patent Number	Title	Estimated Expiration
Japan	2016153420
Spain	2756706
European Patent Office	2442821	ADMINISTRATION SÛRE DE DESMOPRESSINE (SAFE DESMOPRESSIN ADMINISTRATION)
Spain	2559446

Supplementary Protection Certificates for desmopressin acetate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3225249	300983	Netherlands		PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
2712622	PA2017001,C2712622	Lithuania		PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008
2712622	LUC00015	Luxembourg		PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
3225249	CA 2019 00023	Denmark		PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504

Investment Scenario, Market Dynamics, and Financial Trajectory for Desmopressin Acetate

Last updated: February 3, 2026

Summary

Desmopressin acetate, a synthetic analog of vasopressin, is primarily used in managing central diabetes insipidus, bedwetting, and certain coagulation disorders. The global market for desmopressin acetate is anticipated to grow driven by expanding indications, technological advancements, and increased awareness. This report analyzes current market dynamics, investment opportunities, competitive landscape, and financial projections, offering a comprehensive view for stakeholders.

---

What Is Desmopressin Acetate?

Parameter	Details
Drug Class	Vasopressin analog
Approved Indications	Diabetes insipidus, nocturnal enuresis, hemophilia A, von Willebrand disease
Administration Forms	Intranasal spray, oral tablets, injectables
Patent/Patent Expiry	Patent expired or nearing expiry for several formulations
Manufacturers	Ferring Pharmaceuticals, Sandoz, Novo Nordisk, Others

---

Market Size and Growth Trajectory

Parameter	2022 Estimates	Projection 2028	CAGR (2023-2028)
Global Market Value	USD 250 million	USD 400 million	8%
Regional Breakdown	North America (40%), Europe (25%), Asia-Pacific (25%), Others (10%)
Drivers of Growth:	Increasing prevalence of conditions treated, expanding indications, rising geriatric population, unmet needs
Potential Market Constraints:	Stringent regulatory environments, competition from biosimilars, supply chain disruptions

Source: MarketsandMarkets, 2022; [1], [2].

---

Market Dynamics

Key Drivers

• Growing Incidence of Disease Conditions

  • Central diabetes insipidus has an estimated prevalence of 1 in 25,000 individuals globally. Rising awareness and improved diagnostics catalyze demand [3].
  • Nocturnal enuresis affects up to 15% of children at age 5, with many transitioning to adult-onset cases, elevating treatment needs [4].

• Expanding Therapeutic Applications

  • Emerging uses in conditions like bleeding disorders enhance drug retargeting.

• Advancements in Delivery Technologies

  • Development of nasal spray and oral formulations enhances patient adherence and opens new markets.

Key Challenges

• Patent Expiry and Generic Competition

  • Several formulations have lost patent protection, increasing price competition and squeezing profit margins.

• Regulatory Hurdles

  • Stringent approval processes in the US, EU, and Asian markets can delay market entry.

• Manufacturing Complexities

  • Peptide stability and manufacturing scalability impact supply consistency and costs.

Competitive Landscape

Major Companies	Market Share (Estimate 2022)	Key Products	Innovation Focus
Ferring Pharmaceuticals	35%	Minirin (intranasal)	Novel formulations, extended-release options
Sandoz (Novartis)	25%	Desmopressin tablets	Biosimilars, cost reduction strategies
Novo Nordisk	10%	Non-coded formulations	Delivery technology, combination therapies
Others	30%	Various generics, regional brands	Local market adaptations

Note: Market share estimates are approximate and based on industry reports [5].

---

Financial Projections Analysis

Revenue Forecasts by Region and Formulation

Region	2023 (USD millions)	2028 (USD millions)	Notes
North America	100	160	Driven by high prevalence and reimbursement coverage
Europe	62.5	100	New formulations gaining approval
Asia-Pacific	50	90	Rising healthcare access, new entrants
Rest of World	37.5	50	Limited but emerging markets

Cost and Profitability Dynamics

Aspect	Details
Manufacturing Costs	Peptide synthesis and stability management impact costs
Pricing Strategies	Premium pricing for novel formulations, discounting in generics
R&D Investment	Approx. 10-15% of revenues in ongoing clinical trials and formulation improvements
Margins	Gross margins estimated at 55-65%, net margins at 15-25% pre-generic entry

Investment Opportunities

• Development of Novel Delivery Systems

  • Long-acting nasal sprays and oral formulations with enhanced bioavailability present lucrative avenues.

• Biosimilar and Generic Competition

  • Opportunities to capture market share post-patent expiry, provided regulatory pathways are streamlined.

• Expanding Indications

  • Investigational uses such as in bleeding management or hormonal regulation warrant strategic R&D focus.

Key M&A and Licensing Trends

Year	Major Deals (USD millions)	Description	Impact
2020	150	Sandoz’s acquisition of desmopressin assets	Strengthening biosimilar portfolio
2021	120	Licensing agreement for new formulations	Accelerated market access and innovation

---

Comparison with Similar Peptide & Hormone Drugs

Drug Class	Key Drugs	Market Size (USD Millions, 2022)	CAGR (2023-2028)	Comments
Vasopressin Analogs	Desmopressin, Vasopressin	500	7-8%	Multiple indications; biosimilar entries exist
Growth Hormone Therapies	Somatropin	4,000	6.5%	Larger market, higher R&D costs
Insulin Analogs	Insulin glargine, Lispro	58 billion	8%	Different class with broader market appeal

---

Regulatory Environment and Patent Landscape

Regulatory Agency	Key Policies Impacting Market	Recent Changes	Implications
US FDA	Strict bioequivalence and safety standards	Office of Generic Drugs emphasizing biosimilars	Increased approval timelines and costs
European Medicines Agency (EMA)	Centralized submission pathways	Streamlined procedures for established generics	Faster market entry for approved biosimilars
China NMPA	Faster approval, expanding local manufacturing	Fast-track approvals for essential medicines	Growing domestic competition

Patent Status	Formulation Type	Expiry Year (Est.)	Implications
Patents expired in 2018-2020	Intranasal, injectable formulations	2024-2030	Increased generic and biosimilar competition
Pending Patents (US/EU)	Novel formulations, delivery mechanisms	2028-2035	Opportunities for innovator companies

---

Concluding Financial and Investment Outlook

Aspect	Summary
Market Growth Potential	Moderate to high growth driven by expanding indications and formulations
Competitive Landscape	Fragmented with significant generic/biosimilar presence
Pricing and Margins	Expected decline in margins for generics; premium for novel formulations
R&D and Innovation	Critical to maintain market share amid patent expiries
Regional Opportunities	Asia-Pacific and emerging markets offer high-growth potential
Regulatory and Patent Risks	Must be actively managed to prevent market erosion

---

Key Takeaways

• Growing Market: The worldwide desmopressin acetate market is projected to grow at a CAGR of approximately 8% from 2023 to 2028, reaching USD 400 million.
• Patent Expiry Impact: Patent expirations are increasing competition, especially from biosimilars, necessitating innovation in delivery and new indications.
• Formulation Innovation: Long-acting nasal sprays and oral tablets are core growth drivers, offering margin expansion.
• Regional Expansion: Asia-Pacific and emerging markets present significant upside, with increased healthcare access and local manufacturing.
• Investment Focus: Opportunities lie in developing novel formulations, obtaining regulatory approvals, and expanding indications through clinical research.
• Market Risks: Regulatory hurdles, pricing pressures, supply chain disruptions, and competitive patent cliffs pose ongoing challenges.

---

FAQs

1. What are the primary indications for desmopressin acetate?
The main indications include central diabetes insipidus, nocturnal enuresis, and certain bleeding disorders such as hemophilia A and von Willebrand disease.

2. How does patent expiration affect the desmopressin market?
Patent expirations lead to increased generic and biosimilar competition, reducing prices and margins, prompting companies to innovate in formulations and expand indications.

3. What are the dominant delivery forms of desmopressin?
Intranasal spray represents the most common form, with oral tablets and injectables as secondary options. Newer formulations include long-acting nasal sprays and oral disintegrating tablets.

4. Which regions offer the highest growth prospects for desmopressin?
Asia-Pacific and Latin America are emerging markets with significant growth potential due to expanding healthcare infrastructure and unmet medical needs.

5. What are the main challenges facing desmopressin manufacturers?
Key challenges include regulatory approvals, manufacturing complexity, patent cliffs, pricing pressures, and maintaining supply chain stability.

---

References

[1] MarketsandMarkets, 2022. Desmopressin Market by Formulation, Indication, and Region.

[2] GlobalData Reports, 2022. Peptide and Hormone Drug Market Analysis.

[3] WHO, 2020. Prevalence of Central Diabetes Insipidus.

[4] American Academy of Pediatrics, 2019. Nocturnal Enuresis Epidemiology.

[5] IQVIA, 2022. Global Pharmaceutical Market Share Data.